ANTI-HELICOBACTER PYLORI COMPOSITIONS CONTAINING 1-METHYLCARBAPENEM DERIVATIVES AS THE ACTIVE INGREDIENT

Abstract: 1-Methylcarbapenem derivatives having the following formula: (wherein, R 1 represents a group of the following formula: R 2 represents a hydrogen atom or an alkyl group and R 3 represents a hydrogen atom or an alkyl group), or pharmacologically acceptable salts or esters thereof are useful as the active ingredient in a composition for an anti- helicobacter pylori (a treatment or prevention of infectious diseases caused by helicobacter pylori , particularly treatment).

Description: [Technical Field] The present invention relates to the use of 1-methylcarbapenem derivatives or pharmacologically acceptable salts or esters thereof in the preparation of an anti- helicobacter pylori medicament. [Background Art] According to recent studies, there are a number of reports on the phenomenon that helicobacter pylori is detected at a high ratio in patients suffering from chronic gastritis or digestive ulcers, and that such gastrointestinal disorders are cured by the eradication of helicobacter pylori; and on the phenomenon that the recurrence ratio of digestive ulcers shows a drastic decrease as a result of the eradication of this bacterium. It is therefore thought that infection with this bacterium relates to chronic and digestive ulcers and, furthermore, it even has a close relationship with gastric cancer or gastritis [G.E. Buck et al., J. Infect. Dis., 153 , 664-669(1986), G. Geis et al., J. Clinical Microbiology, 930-932(1990), etc.]. At present, it is reported that bismuth compounds such as bismuth citrate, nitroimidazole compounds such as metronidazole and antibiotics such as tetracycline, amoxicillin and clarithromycin are effective against helicobacter pylori . None of these compounds has sufficient antibacterial activity and each has a chemical structure markedly different from that of the 1-methylcarbapenem derivatives which are an active ingredient to be employed in the present invention. The 1-methylcarbapenem derivatives, which are an active ingredient of the present invention, are known compounds (for example, Japanese Patent Publication No. Hei 7-45499, Japanese Patent Application Kokai No. Hei 2-223587, Japanese Patent Application Kokai No. Hei 4-279588, Japanese Patent Application Kokai No. Hei 8-53453 etc.), but their anti -helicobacter pylori activity is not known at all. [Disclosure of the Invention] The present inventors have carried out an extensive investigation into the antibacterial activity of 1-methylcarbapenem derivatives. As a result, it has been found that specific 1-methylcarbapenem derivatives have excellent anti- helicobacter pylori activity and are useful as an active ingredient in an anti -helicobacter pylori composition (treatment or prevention of infectious diseases caused by helicobacter pylori , particularly, treatment). The present invention provides the use of 1-methylcarbapenem derivatives or pharmacologically acceptable salts or esters thereof in the preparation of an anti- helicobacter pylori medicament. Thus, there is provided the use of a compound of formula (I), as defined below, or a pharmacologically acceptable salt or ester thereof, in the manufacture of a medicament for the prophylaxis or treatment of infectious diseases caused by helicobacter pylori : wherein R 1 represents a group of the following formula: R 2 represents a hydrogen atom or a C 1- C 6 alkyl group, and R 3 represents a hydrogen atom or a C 1- C 6 alkyl group. In the above formula (I), examples of the C 1- C 6 alkyl group of R 2 or R 3 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl and hexyl groups, preferably the C 1- C 4 alkyl groups, more preferably the methyl or ethyl group and most preferably the methyl group. R 1 is preferably the group of the formula (IIa). The oxopyrrolidinyl part of the group of the formula (IIa) is preferably a 2-oxo-3-pyrrolidinyl or 2-oxo-4-pyrrolidinyl group and most preferably the 2-oxo-4-pyrrolidinyl group. The thioxopyrrolidinyl part of the group of the formula (IId) is preferably a 2-thioxo-3-pyrrolidinyl or 2-thioxo-4-pyrrolidinyl group, and most preferably the 2-thioxo-4-pyrrolidinyl group. The pharmacologically acceptable salts of Compound (I) which are also an active ingredient for use in the present invention are salts of Compound (I) which exhibit antibacterial activity and are usable as a medicament when administered to a living body. Examples include inorganic salts such as lithium salts, sodium salts, potassium salts, calcium salts and magnesium salts; ammonium salts; and organic amine salts such as triethylamine salts, diisopropylamine salts and cyclohexylamine salts; preferably lithium salts, sodium salts and potassium salts; more preferably sodium salts and potassium salts; and most preferably sodium salts. The pharmacologically acceptable esters of Compound (I) which are also an active ingredient for use in the present invention are esters of the compound (I) which exhibit antibacterial activity and are usable as a medicament when administered to a living body; and preferably esters which can be hydrolyzed in vivo and converted to the corresponding carboxylic acids. Specific examples include: C 1- C 4 alkyl esters (preferably, methyl and ethyl esters), C 1- C 4 alkoxycarbonyloxy-(C 1 -C 4 alkyl) esters [for example, methoxycarbonyloxymethyl esters, 1-(methoxycarbonyloxy)ethyl esters, ethoxycarbonyloxymethyl esters, 1-(ethoxycarbonyloxy)ethyl esters, propoxycarbonyloxymethyl esters, 1-(propoxycarbonyloxy)ethyl esters, isopropoxycarbonyloxymethyl esters, 1-(isopropoxycarbonyloxy)ethyl esters, butoxycarbonyloxymethyl esters, 1-(butoxycarbonyloxy)ethyl esters, isobutoxycarbonyloxymethyl esters, 1-(isobutoxycarbonyloxy)ethyl esters, t-butoxycarbonyloxymethyl esters, 1-(t-butoxycarbonyloxy)ethyl esters, 1-(t-butoxycarbonyloxy)propyl esters and 1-(t-butoxycarbonyloxy)butyl esters, of which the methoxycarbonyloxymethyl esters, 1-(methoxycarbonyloxy)ethyl esters, ethoxycarbonyloxymethyl esters, 1-(ethoxycarbonyloxy)ethyl esters, isopropoxycarbonyloxymethyl esters, 1-(isopropoxycarbonyloxy)ethyl esters, t-butoxycarbonyloxymethyl esters or 1-(t-butoxycarbonyloxy)ethyl esters are preferred, the 1-(methoxycarbonyloxy)ethyl esters, 1-(ethoxycarbonyloxy)ethyl esters, 1-(isopropoxycarbonyloxy)ethyl esters, t-butoxycarbonyloxymethyl esters and 1-(t-butoxycarbonyloxy)ethyl esters being more preferred and the 1-(isopropoxycarbonyloxy)ethyl esters being most preferred]; C 5 -C 6 cycloalkyloxycarbonyloxy-(C 1- C 4 alkyl) esters [for example, cyclopentyloxycarbonyloxymethyl esters, 1-(cyclopentyloxycarbonyloxy)ethyl esters, cyclohexyloxycarbonyloxymethyl esters, 1-(cyclohexyloxycarbonyloxy)ethyl esters, 1-(cyclohexyloxycarbonyloxy)propyl esters and 1-(cyclohexyloxycarbonyloxy)butyl esters, of which the cyclopentyloxycarbonyloxymethyl esters, 1-(cyclopentyloxycarbonyloxy)ethyl esters, cyclohexyloxycarbonyloxymethyl esters and 1-(cyclohexyloxycarbonyloxy)ethyl esters are preferred, the 1-(cyclopentyloxycarbonyloxy)ethyl esters and 1-(cyclohexyloxycarbonyloxy)ethyl esters being more preferred, and the 1-(cyclohexyloxycarbonyloxy)ethyl esters being most preferred; C 2- C 5 alkanoyloxy-(C 1- C 4 alkyl) esters [for example, acetoxymethyl esters, 1-(acetoxy)ethyl esters, 1-(acetoxy)propyl esters, 1-(acetoxy)butyl esters, propionyloxymethyl esters, 1-(propionyloxy)ethyl esters, butyryloxymethyl esters, 1-(butyryloxy)ethyl esters, isobutyryloxymethyl esters, 1-(isobutyryloxy)ethyl esters, 1-(isobutyryloxy)propyl esters, 1-(isobutyryloxy)butyl esters, pivaloyloxymethyl esters, 1-(pivaloyloxy)ethyl esters, 1-(pivaloyloxy)propyl esters and 1-(pivaloyloxy)butyl esters, of which the acetoxymethyl esters, 1-(acetoxy)ethyl esters, propionyloxymethyl esters, 1-(propionyloxy)ethyl esters, butyryloxymethyl esters, 1-(butyryloxy)ethyl esters, isobutyryloxymethyl esters, 1-(isobutyryloxy)ethyl esters, pivaloyloxymethyl esters and 1-(pivaloyloxy)ethyl esters are preferred, the acetoxymethyl esters, 1-(acetoxy)ethyl esters, isobutyryloxymethyl esters, 1-(isobutyryloxy)ethyl esters, pivaloyloxymethyl esters and 1-(pivaloyloxy)ethyl esters being more preferred, and the pivaloyloxymethyl esters being most preferred]; (C 5- C 6 cycloalkylcarbonyloxy)- or (1-alkyl-C 5- C 6 cycloalkylcarbonyloxy)-(C 1- C 4 alkyl) esters [for example, cyclopentylcarbonyloxymethyi esters, 1-(cyclopentylcarbonyloxy)ethyl esters, 1-methylcyclopentylcarbonyloxymethyl esters, 1-(1-methylcyclopentylcarbonyloxy)ethyl esters, 1-ethylcyclopentylcarbonyloxymethyl esters, 1-(1-ethylcyclopentylcarbonyloxy)ethyl esters, cyclohexylcarbonyloxymethyl esters, 1-(cyclohexylcarbonyloxy)ethyl esters, 1-(cyclohexylcarbonyloxy)propyl esters, 1-(cyclohexylcarbonyloxy)butyl esters, 1-methylcyclohexylcarbonyloxymethyl esters, 1-(1-methylcyclohexylcarbonyloxy)ethyl esters, 1-(1-methylcyclohexylcarbonyloxy)propyl esters, 1-(1-methylcyclohexylcarbonyloxy)butyl esters, 1-ethylcyclohexylcarbonyloxymethyl esters, 1-(1-ethylcyclohexylcarbonyloxy)ethyl esters, 1-propylcyclohexylcarbonyloxymethyl esters and 1-butylcyclohexylcarbonyloxymethyl esters, of which the cyclopentylcarbonyloxymethyl esters, 1-(cyclopentylcarbonyloxy)ethyl esters, 1-methylcyclopentylcarbonyloxymethyl esters, 1-(1-methylcyclopentylcarbonyloxy)ethyl esters, 1-ethylcyclopentylcarbonyloxymethyl esters, cyclohexylcarbonyloxymethyl esters, 1-(cyclohexylcarbonyloxy)ethyl esters, 1-methylcyclohexylcarbonyloxymethyl esters, 1-(1-methylcyclohexylcarbonyloxy)ethyl esters and 1-ethylcyclohexylcarbonyloxymethyl esters are preferred, the cyclopentylcarbonyloxymethyl esters, 1-(cyclopentylcarbonyloxy)ethyl esters, 1-methylcyclopentylcarbonyloxymethyl esters, 1-(1-methylcyclopentylcarbonyloxy)ethyl esters, cyclohexylcarbonyloxymethyl esters, 1-(cyclohexylcarbonyloxy)ethyl esters, 1-methylcyclohexylcarbonyloxymethyl esters and 1-(1-methylcyclohexylcarbonyloxy)ethyl esters being more preferred, the cyclopentylcarbonyloxymethyl esters, 1-methylcyclopentylcarbonyloxymethyl esters, cyclohexylcarbonyloxymethyl esters and 1-methylcyclohexylcarbonyloxymethyl esters being much more preferred, and the 1-methylcyclohexylcarbonyloxymethyl esters being most preferred]; phthalidyl esters; and 5-(C 1- C 4 alkyl- or phenyl-)-2-oxo-1,3-dioxolen-4-ylmethyl esters [for example, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters, 5-ethyl-2-oxo-1,3-dioxolen-4-ylmethyl esters, 5-propyl-2-oxo-1,3-dioxolen-4-ylmethyl esters, 5-butyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl esters, of which the 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters, 5-ethyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl esters are preferred, the 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl esters being more preferred, and the 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters being most preferred]. Among these esters, the methoxycarbonyloxymethyl esters, 1-(methoxycarbonyloxy)ethyl esters, ethoxycarbonyloxymethyl esters, 1-(ethoxycarbonyloxy)ethyl esters, isopropoxycarbonyloxymethyl esters, 1-(isopropoxycarbonyloxy)ethyl esters, t-butoxycarbonyloxymethyl esters, 1-(t-butoxycarbonyloxy)ethyl esters, cyclopentyloxycarbonyloxymethyl esters, 1-(cyclopentyloxycarbonyloxy)ethyl esters, cyclohexyloxycarbonyloxymethyl esters, 1-(cyclohexyloxycarbonyloxy)ethyl esters, acetoxymethyl esters, 1-(acetoxy)ethyl esters, propionyloxymethyl esters, 1-(propionyloxy)ethyl esters, butyryloxymethyl esters, 1-(butyryloxy)ethyl esters, isobutyryloxymethyl esters, 1-(isobutyryloxy)ethyl esters, pivaloyloxymethyl esters, 1-(pivaloyloxy)ethyl esters, cyclopentylcarbonyloxymethyl esters, 1-(cyclopentylcarbonyloxy)ethyl esters, 1-methylcyclopentylcarbonyloxymethyl esters, 1-(1-methylcyclopentylcarbonyloxy)ethyl esters, 1-ethylcyclopentylcarbonyloxymethyl esters, cyclohexylcarbonyloxymethyl esters, 1-(cyclohexylcarbonyloxy)ethyl esters, 1-methylcyclohexylcarbonyloxymethyl esters, 1-(1-methylcyclohexylcarbonyloxy)ethyl esters, 1-ethylcyclohexylcarbonyloxymethyl esters, phthalidyl esters, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters, 5-ethyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl esters are preferred; the 1-(methoxycarbonyloxy)ethyl esters, 1-(ethoxycarbonyloxy)ethyl esters, 1-(isopropoxycarbonyloxy)ethyl esters, t-butoxycarbonyloxymethyl esters, 1-(t-butoxycarbonyloxy)ethyl esters, 1-(cyclopentyloxycarbonyloxy)ethyl esters, 1-(cyclohexyloxycarbonyloxy)ethyl esters, acetoxymethyl esters, 1-(acetoxy)ethyl esters, isobutyryloxymethyl esters, 1-(isobutyryloxy)ethyl esters, pivaloyloxymethyl esters, 1-(pivaloyloxy)ethyl esters, cyclopentylcarbonyloxymethyl esters, 1-(cyclopentylcarbonyloxy)ethyl esters, 1-methylcyclopentylcarbonyloxymethyl esters, 1-(1-methylcyclopentylcarbonyloxy)ethyl esters, cyclohexylcarbonyloxymethyl esters, 1-(cyclohexylcarbonyloxy)ethyl esters, 1-methylcyclohexylcarbonyloxymethyl esters, 1-(1-methylcyclohexylcarbonyloxy)ethyl esters, phthalidyl esters, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl esters are more preferred; the 1-(methoxycarbonyloxy)ethyl esters, 1-(ethoxycarbonyloxy)ethyl esters, 1-(isopropoxycarbonyloxy)ethyl esters, t-butoxycarbonyloxymethyl esters, 1-(t-butoxycarbonyloxy)ethyl esters, 1-(cyclopentyloxycarbonyloxy)ethyl esters, 1-(cyclohexyloxycarbonyloxy)ethyl esters, acetoxymethyl esters, 1-(acetoxy)ethyl esters, isobutyryloxymethyl esters, 1-(isobutyryloxy)ethyl esters, pivaloyloxymethyl esters, 1-(pivaloyloxy)ethyl esters, cyclopentylcarbonyloxymethyl esters, 1-methylcyclopentylcarbonyloxymethyl esters, cyclohexylcarbonyloxymethyl esters, 1-methylcyclohexylcarbonyloxymethyl esters, phthalidyl esters and 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters are still more preferred; the 1-(isopropoxycarbonyloxy)ethyl esters, 1-(cyclohexyloxycarbonyloxy)ethyl esters, pivaloyloxymethyl esters, 1-methylcyclohexylcarbonyloxymethyl esters and 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters are particularly preferred; and the 1-(isopropoxycarbonyloxy)ethyl esters, 1-(cyclohexyloxycarbonyloxy)ethyl esters and pivaloyloxymethyl esters are most preferred. Compound (I) which is an active ingredient for use in the present invention contains asymmetric carbons in its molecule and therefore has various isomers with respect to them. The present application embraces the use of various isomers of Compound (I) and mixtures of these isomers, of which the isomers having a (1R,5S,6S) configuration and an R configuration for the hydroxyl group at the α-position of the 6-substituent in the carbapenem skeleton, are preferred. The present application also embraces the use of hydrated products of Compound (I) and its salts and esters. Preferred examples of the compounds of formula (I) include: (1) a compound wherein R 1 represents a group of formula (IIa) (in which R 2 represents a hydrogen atom or a C 1- C 4 alkyl group), a group of formula (IIb), a group of formula (IIc) or a group of formula (IId) (in which R 3 represents a hydrogen atom or a methyl group), (2) a compound wherein R 1 represents a group of formula (IIa) (in which R 2 represents a hydrogen atom or a methyl group), (3) a compound wherein R 1 represents a 2-oxo-3-pyrrolidinyl, 1-methyl-2-oxo-3-pyrrolidinyl, 2-oxo-4-pyrrolidinyl or 1-methyl-2-oxo-4-pyrrolidinyl group, (4) a compound wherein R 1 represents a 2-oxo-4-pyrrolidinyl or 1-methyl-2-oxo-4-pyrrolidinyl group, (5) a compound wherein R 1 represents a 2-oxo-4-pyrrolidinyl group, (6) a compound wherein the configuration in the carbapenem skeleton is a (1R,5S,6S) configuration, (7) a compound wherein the configuration of the hydroxyl group at the α-position of the 6-substituent in the carbapenem skeleton is a R configuration, (8) a compound whose pharmacologically acceptable salt is a lithium salt, sodium salt or potassium salt, (9) a compound whose pharmacologically acceptable salt is a sodium salt or potassium salt, (10) a compound whose pharmacologically acceptable salt is a sodium salt, (11) a compound whose pharmacologically acceptable ester can be hydrolyzed in vivo and converted into the corresponding carboxylic acid, (12) a compound whose pharmacologically acceptable ester is a 1-(methoxycarbonyloxy)ethyl ester, 1-(ethoxycarbonyloxy)ethyl ester, 1-(isopropoxycarbonyloxy)ethyl ester, t-butoxycarbonyloxymethyl ester, 1-(t-butoxycarbonyloxy)ethyl ester, 1-(cyclopentyloxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, acetoxymethyl ester, 1-(acetoxy)ethyl ester, isobutyryloxymethyl ester, 1-(isobutyryloxy)ethyl ester, pivaloyloxymethyl ester, 1-(pivaloyloxy)ethyl ester, cyclopentylcarbonyloxymethyl ester, 1-(cyclopentylcarbonyloxy)ethyl ester, 1-methylcyclopentylcarbonyloxymethyl ester, 1-(1-methylcyclopentylcarbonyloxy)ethyl ester, cyclohexylcarbonyloxymethyl ester, 1-(cyclohexylcarbonyloxy)ethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester, 1-(1-methylcyclohexylcarbonyloxy)ethyl ester, phthalidyl ester, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester or 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl ester, (13) a compound whose pharmacologically acceptable ester is a 1-(methoxycarbonyloxy)ethyl ester, 1-(ethoxycarbonyloxy)ethyl ester, 1-(isopropoxycarbonyloxy)ethyl ester, t-butoxycarbonyloxymethyl ester, 1-(t-butoxycarbonyloxy)ethyl ester, 1-(cyclopentyloxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, acetoxymethyl ester, 1-(acetoxy)ethyl ester, isobutyryloxymethyl ester, 1-(isobutyryloxy)ethyl ester, pivaloyloxymethyl ester, 1-(pivaloyloxy)ethyl ester, cyclopentylcarbonyloxymethyl ester, 1-methylcyclopentylcarbonyloxymethyl ester, cyclohexylcarbonyloxymethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester, phthalidyl ester or 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester, (14) a compound whose pharmacologically acceptable ester is a 1-(isopropoxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, pivaloyloxymethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester or 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester, and (15) a compound whose pharmacologically acceptable ester is a 1-(isopropoxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester or pivaloyloxymethyl ester. In each of the groups (1) to (5), (8) to (10) and (11) to (15), the larger the number is, the more preferred the compound is.In addition, compounds obtained by selecting R 1 from the group (1) to (5), a configuration from (6) or (7), a salt from the group (8) to (10) and an ester from the group (11) to (15) and by using these in any combination are preferred. Examples of such compounds are as follows: (16) a compound wherein R 1 represents a group of formula (IIa) (in which R 2 represents a hydrogen atom or a C 1- C 4 alkyl group), group of formula (IIb), group of formula (IIc) or group of formula (IId) (in which R 3 represents a hydrogen atom or a methyl group), the configuration in the carbapenem skeleton is a (1R,5S,6S) configuration, the configuration of the hydroxyl group at the α-position of the 6-substituent in the carbapenem skeleton is a R configuration, the pharmacologically acceptable salt is a lithium salt, sodium salt or potassium salt, and the pharmacologically acceptable ester is one which can be hydrolyzed in vivo and converted into the corresponding carboxylic acid. (17) a compound wherein R 1 represents a group of formula (IIa) (in which R 2 represents a hydrogen atom or a methyl group), the configuration in the carbapenem skeleton is a (1R,5S,6S) configuration, the configuration of the hydroxyl group at the α-position of the 6-substituent in the carbapenem skeleton is a R configuration, the pharmacologically acceptable salt is a sodium salt or potassium salt, and the pharmacologically acceptable ester is a 1-(methoxycarbonyloxy)ethyl ester, 1-(ethoxycarbonyloxy)ethyl ester, 1-(isopropoxycarbonyloxy)ethyl ester, t-butoxycarbonyloxymethyl ester, 1-(t-butoxycarbonyloxy)ethyl ester, 1-(cyclopentyloxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, acetoxymethyl ester, 1-(acetoxy)ethyl ester, isobutyryloxymethyl ester, 1-(isobutyryloxy)ethyl ester, pivaloyloxymethyl ester, 1-(pivaloyloxy)ethyl ester, cyclopentylcarbonyloxymethyl ester, 1-(cyclopentylcarbonyloxy)ethyl ester, 1-methylcyclopentylcarbonyloxymethyl ester, 1-(1-methylcyclopentylcarbonyloxy)ethyl ester, cyclohexylcarbonyloxymethyl ester, 1-(cyclohexylcarbonyloxy)ethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester, 1-(1-methylcyclohexylcarbonyloxy)ethyl ester, phthalidyl ester, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester or 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl ester, (18) a compound wherein R 1 represents a 2-oxo-3-pyrrolidinyl group, 1-methyl-2-oxo-3-pyrrolidinyl group, 2-oxo-4-pyrrolidinyl group or 1-methyl-2-oxo-4-pyrrolidinyl group, the configuration in the carbapenem skeleton is a (1R,5S,6S) configuration, the configuration of the hydroxyl group at the α-position of the 6-substituent in the carbapenem skeleton is a R configuration, the pharmacologically acceptable salt is a sodium salt or potassium salt, and the pharmacologically acceptable ester is a 1-(methoxycarbonyloxy)ethyl ester, 1-(ethoxycarbonyloxy)ethyl ester, 1-(isopropoxycarbonyloxy)ethyl ester, t-butoxycarbonyloxymethyl ester, 1-(t-butoxycarbonyloxy)ethyl ester, 1-(cyclopentyloxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, acetoxymethyl ester, 1-(acetoxy)ethyl ester, isobutyryloxymethyl ester, 1-(isobutyryloxy)ethyl ester, pivaloyloxymethyl ester, 1-(pivaloyloxy)ethyl ester, cyclopentylcarbonyloxymethyl ester, 1-methylcyclopentylcarbonyloxymethyl ester, cyclohexylcarbonyloxymethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester, phthalidyl ester or 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester, (19) compounds wherein R 1 represents a 2-oxo-4-pyrrolidinyl group or 1-methyl-2-oxo-4-pyrrolidinyl group, the configuration in the carbapenem skeleton is a (1R,5S,6S) configuration, the configuration of the hydroxyl group at the α-position of the 6-substituent in the carbapenem skeleton is a R configuration, the pharmacologically acceptable salt is a sodium salt or potassium salt, and the pharmacologically acceptable ester is a 1-(isopropoxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, pivaloyloxymethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester or 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester, and (20) a compound wherein R 1 represents a 2-oxo-4-pyrrolidinyl group, the configuration in the carbapenem skeleton is a (1R,5S,6S) configuration, the configuration of the hydroxyl group at the α-position of the 6-substituent in the carbapenem skeleton is R a configuration, the pharmacologically acceptable salt is a sodium salt, and the pharmacologically acceptable ester is a 1-(isopropoxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester or pivaloyloxymethyl ester. Specific examples of the compounds represented by the formula (I) can be exemplified in Table 1. Compound No. R R 1 a 1 H 2-oxo-4-Pyrr 2 Na 2-oxo-4-Pyrr 3 K 2-oxo-4-Pyrr 4 MeOCO 2 CHMe 2-oxo-4-Pyrr 5 EtOCO 2 CHMe 2-oxo-4-Pyrr 6 Pr i OCO 2 CHMe 2-oxo-4-Pyrr 7 Bu t OCO 2 CH 2 2-oxo-4-Pyrr 8 Bu t OCO 2 CHMe 2-oxo-4-Pyrr 9 Pn c OCO 2 CHMe 2-oxo-4-Pyrr 10 Hx c OCO 2 CHMe 2-oxo-4-Pyrr 11 AcOCH 2 2-oxo-4-Pyrr 12 AcOCHMe 2-oxo-4-Pyrr 13 Pr i CO 2 CH 2 2-oxo-4-Pyrr 14 Bu t CO 2 CH 2 2-oxo-4-Pyrr 15 Pn c CO 2 CH 2 2-oxo-4-Pyrr 16 1-MePn c CO 2 CH 2 2-oxo-4-Pyrr 17 Hx c CO 2 CH 2 2-oxo-4-Pyrr 18 1-MeHx 6 COCH 2 2-oxo-4-Pyrr 19 Phthz 2-oxo-4-Pyrr 20 MODM 2-oxo-4-Pyrr 21 H 1-Me-2-oxo-4-Pyrr 22 Na 1-Me-2-oxo-4-Pyrr 23 K 1-Me-2-oxo-4-Pyrr 24 MeOCO 2 CHMe 1-Me-2-oxoA-Pyrr 25 EtOCO 2 CHMe 1-Me-2-oxo-4-Pyrr 26 Pr i OCO 2 CHMe 1-Me-2-oxo-4-Pyrr 27 Bu t OCO 2 CH 2 1-Me-2-oxo-4-Pyrr 28 Bu t OCO 2 CHMe 1-Me-2-oxo-4-Pyrr 29 Pn c OCO 2 CHMe 1-Me-2-oxo-4-Pyrr 30 Hx c OCO 2 CHMe 1-Me-2-oxo-4-Pyrr 31 AcOCH 2 1-Me-2-oxo-4-Pyrr 32 AcOCHMe 1-Me-2-oxo-4-Pyrr 33 Pr i CO 2 CH 2 1-Me-2-oxo-4-Pyrr 34 Bu t CO 2 CH 2 1-Me-2-oxo-4-Pyrr 35 Pn c CO 2 CH 2 1-Me-2-oxo-4-Pyrr 36 1-MePn c CO 2 CH 2 1-Me-2-oxo-4-Pyrr 37 Hx c CO 2 CH 2 1-Me-2-oxo-4-Pyrr 38 1-MeHx c CO 2 CH 2 1-Me-2-oxo-4-Pyrr 39 Phthz 1-Me-2-oxo-4-Pyrr 40 MODM 1-Me-2-oxo-4-Pyrr 41 H 2-oxo-3-Pyrr 42 Na 2-oxo-3-Pyrr 43 K 2-oxo-3-Pyrr 44 MeOCO 2 CHMe 2-oxo-3-Pyrr 45 EtOCO 2 CHMe 2-oxo-3-Pyrr 46 Pr i OCO 2 CHMe 2-oxo-3-Pyrr 47 Bu t OCO 2 CH 2 2-oxo-3-Pyrr 48 Bu t OCO 2 CHMe 2-oxo-3-Pyrr 49 AcOCH 2 2-oxo-3-Pyrr 50 AcOCHMe 2-oxo-3-Pyrr 51 Pr i CO 2 CH 2 2-oxo-3-Pyrr 52 Bu t CO 2 CH 2 2-oxo-3-Pyrr 53 1-MePn c CO 2 CH 2 2-oxo-3-Pyrr 54 1-MeHx c CO 2 CH 2 2-oxo-3-Pyrr 55 Phthz 2-oxo-3-Pyrr 56 MODM 2-oxo-3-Pyrr 57 H 1-Me-2-oxo-3-Pyrr 58 Na 1-Me-2-oxo-3-Pyrr 59 K 1-Me-2-oxo-3-Pyrr 60 MeOCO 2 CHMe 1-Me-2-oxo-3-Pyrr 61 Pr i OCO 2 CHMe 1-Me-2-oxo-3-Pyrr 62 Bu t OCO 2 CH 2 1-Me-2-oxo-3-Pyrr 63 Bu t OCO 2 CHMe 1-Me-2-oxo-3-Pyrr 64 AcOCH 2 1-Me-2-oxo-3-Pyrr 65 AcOCHMe 1-Me-2-oxo-3-Pyrr 66 Pr i CO 2 CH 2 1-Me-2-oxo-3-Pyrr 67 Bu t CO 2 CH 2 1-Me-2-oxo-3-Pyrr 68 1-MePn c CO 2 CH 2 1-Me-2-oxo-3-Pyrr 69 1-MeHx c CO 2 CH 2 1-Me-2-oxo-3-Pyrr 70 Phthz 1-Me-2-oxo-3-Pyrr 71 MODM 1-Me-2-oxo-3-Pyrr 72 H ImdzoPyrr 73 Na ImdzoPyrr 74 K ImdzoPyrr 75 Pr i OCO 2 CHMe ImdzoPyrr 76 Bu t CO 2 CH 2 ImdzoPyrr 77 Hx c CO 2 CHMe ImdzoPyrr 78 H ThizAze 79 Na ThizAze 80 K ThizAze 81 Pr i OCO 2 CHMe ThizAze 82 Bu t CO 2 CH 2 ThizAze 83 Hx c CO 2 CHMe ThizAze 84 H 2-thioxo-4-Pyrr 85 Na 2-thioxo-4-Pyrr 86 K 2-thioxo-4-Pyrr 87 Pr i OCO 2 CHMe 2-thioxo-4-Pyrr 88 Bu t CO 2 CH 2 2-thioxo-4-Pyrr 89 Hx c CO 2 CHMe 2-thioxo-4-Pyrr 90 H 1-Me-2-thioxo-4-Pyrr 91 Na 1-Me-2-thioxo-4-Pyrr 92 K 1-Me-2-thioxo-4-Pyrr 93 Pr i OCO 2 CHMe 1-Me-2-thioxo-4-Pyrr 94 Bu t CO 2 CH 2 1-Me-2-thioxo-4-Pyrr 95 Hx c CO 2 CHMe 1-Me-2-thioxo-4-Pyrr In the above Table, abbreviations represent the following groups, respectively. Ac: acetyl Bu t : t-butyl Et: ethyl Hx c : cyclohexyl ImdzoPyrr: group of the formula (IIb) Me: methyl MODM: 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl Phthz: phthalidyl Pn c : cyclopentyl Pr i : isopropyl Pyrr: pyrrolidinyl ThizAze: group of the formula (IIc) In the above table, the following compounds are preferred: Compounds Nos. 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 20, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 40, 73, 76, 79, 82, 83, 85, 88, 91 and 94; the following compounds are more preferred: Compounds Nos. 2, 6, 10, 14, 18, 22, 26, 30, 34 and 38; and the following compounds are much more preferred: Compound No. 2: sodium 2-(2-oxo-4-pyrrolidinylthio)-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate, Compound No. 14: pivaloyloxymethyl 2-(2-oxo-4-pyrrolidinylthio)-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate, Compound No. 18: 1-methylcyclohexylcarbonyloxymethyl 2-(2-oxo-4-pyrrolidinylthio)-6-( 1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate, Compound No. 22: sodium 2-(1-methyl-2-oxo-4-pyrrolidinylthio)-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate, and Compound No. 34: pivaloyloxymethyl 2-(1-methyl-2-oxo-4-pyrrolidinylthio)-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate. On the other hand, the following compounds are most preferred: (1R,5S,6S)-2-[(4R)-2-oxo-4-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid, or the sodium salt or pivaloyloxymethyl ester thereof; (1R,5S,6S)-2-[(4S)-2-oxo-4-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid, or the sodium salt or pivaloyloxymethyl ester thereof; (1R,5S,6S)-2-[(4R)-1-methyl-2-oxo-4-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid, or sodium salt or pivaloyloxymethyl ester thereof; and (1R,5S,6S)-2-[(4S)-1-methyl-2-oxo-4-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid, or sodium salt or pivaloyloxymethyl ester thereof. Compounds (I), each of which is an active ingredient for use in the present invention, are known or can be prepared easily by a known method (for example Japanese Patent Application Kokai No. Hei 7-165759, Japanese Patent Application Kokai No. Hei 2-223587, Japanese Patent Application Kokai No. Hei 8-53453, Japanese Patent Application Kokai No. Hei 4-279588, etc.). The 1-methylcarbapenem derivatives of formula (I), active ingredients for use in the present invention, have excellent anti-bacterial activity against various helicobacter pylori and lower toxicity, and so they are useful in the manufacture of an anti-bacterial agent for the treatment or prevention (particularly, treatment) of infectious diseases caused by helicobacter pylori . [Capability of Utility in Industry] When the Compound (I) is used in the manufacture of an anti-bacterial agent, Compound (I) by itself or a mixture with a pharmacologically acceptable excipient, diluent, etc., can be administered orally in the form of tablets, capsules, granules, powders or syrups or parenterally in the form of injections. Of these, oral administration is recommended. The above formulations can be prepared in a known manner by using additives. Examples of the additives include an excipient (for example sugar derivatives such as lactose, sucrose, glucose mannitol and sorbitol; starch derivatives such as corn starch, potato starch, α-starch, dextrin and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, low-substituted hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium and internally-crosslinked carboxymethyl cellulose sodium; gum arabic; dextran; pullulan; silicate derivatives such as soft silicic acid anhydride, synthetic aluminum silicate and magnesium aluminate metasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate), a binder (for example the above-exemplified excipients, gelatin, polyvinyl pyrrolidone and Macrogol), a disintegrator (for example the above-exemplified excipients, chemically-modified starch or cellulose derivatives such as croscarmellose sodium, carboxymethyl starch sodium and crosslinked polyvinyl pyrrolidone), a lubricant (for example talc, stearic acid, metal salts of stearic acid such as calcium stearate and magnesium stearate; colloidal silica; waxes such as veegum and spermaceti; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid; sodium carboxylates such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as silicic acid anhydride and silicic acid hydrate; and the same starch derivatives as those exemplified for the excipient), a stabilizer (for example parahydroxybenzoates such as methyl paraben and propyl paraben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenol derivatives such as phenol and cresol; thimerosal; acetic anhydride; and sorbic acid), a corrigent (for example, ordinarily-employed sweeteners, acidifiers and flavors), a diluent and a solution-forming agent for injections (for example, water, ethanol and glycerin). The dose of Compound (I) will vary depending upon the condition and age of the patient. Orally, it is,administered in an amount of 30 mg (preferably 50 mg) in a single dose as a lower limit and 5000 mg (preferably 300 mg) in a single dose as an upper limit, and intravenously, it is administered in an amount of 10 mg (preferably 30 mg) in a single dose as a lower limit and 3000 mg (preferably 200 mg) in a single dose as an upper limit to a human adult. It is desirable to be administered one to six times per day depending upon the conditions of the patient. The anti- helicobacter pylori agent which contains Compound (I) of the present invention as an active ingredient may contain one or more other medicaments in addition. Any medicament that does not have adverse effects on Compound (I) of the present invention can be used. Examples include bismuth preparations (such as bismuth citrate and bismuth salicylate), nitroimidazole compounds (such as metronidazole), H 2 blocker type anti-ulceratives (such as cimetidine, ranitidine hydrochloride, famotidine, roxatidine acetate hydrochloride and nizatidine), proton-pump inhibitor type anti-ulceratives (such as omeprazole, lansoprazole, rabeprazole, reminoprazole and saviprazole), mucous membrane protective factor enhancer type anti-ulceratives (such as plaunotol, teprenone and sofalcone), anti-bacterials (such as clarithromycin, azithromycin, erythromycin, roxithromycin and amoxicillin) and synthetic anti-bacterials (such as ofloxacin, levofloxacin, ciprofloxacin); preferably the bismuth preparations, nitroimidazole compounds, H 2 blocker type anti-ulceratives, proton-pump anti-ulceratives and mucous membrane protective factor enhancer type anti-ulceratives; more preferably, cimetidine, ranitidine hydrochloride, famotidine, roxatidine acetate hydrochloride, nizatidine, omeprazole, lansoprazole, rabeprazole, reminoprazole and saviprazole; and most preferably cimetidine, ranitidine hydrochloride, famotidine, omeprazole and lansoprazole. [Best Modes for Carrying Out the Invention] The present invention will hereinafter be described more specifically by tests and preparation examples. It should, however, be understood that the present invention is not limited by these examples. (Test 1) In vitro activity against helicobacter pylori (MIC: µg/ml) Helicobacter pylori ( H. pylori) from storage was smeared on a 7%-equinedefibrinated-blood-added brain heart infusion agar (BHIA) plate and cultured at 37°C for 72 hours under microaerophilic and wet conditions. The colonies thus grown were picked and suspended in physiological saline to prepare a culture solution of 10 8 CFU/ml (viable microbe cell number per ml). The resulting culture solution was diluted to 10 to 50-fold with physiological saline, and one spot (about 10 µl) of the solution was inoculated on each of medicament-containing and medicament-free BHIA plates. Each of the plates was cultured at 37°C for 72 hours under microaerophilic and wet conditions and the minimum inhibitory concentration (MIC: µg/ml) at which the growth of the colonies was inhibited was measured. The results are shown in Table 2. In vitro antibacterial activity (minimum inhibitory concentration, MIC: µg/ml) No. of helicobacter pylori strain MIC (µg/ml) Compound No. 1 Compound No.2 Compound No. 3 AMPC CAM 9470 ≦0.006 ≦0.006 ≦0.006 0.012 0.006 9472 ≦0.006 ≦0.006 ≦0.006 0.025 0.006 9474 ≦0.006 - - 0.05 0.025 9824 ≦0.006 ≦0.006 ≦0.006 0.39 1.5 9828 ≦0.006 ≦0.006 ≦0.006 0.20 6.25 In the above Table 2, Compound 1 is sodium (1R,5S,6S)-2-[(4R)-2-oxo-4-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate, Compound 2 is sodium (1R,5S,6S)-2-[(4R)-1-methyl-2-oxo-4-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate, Compound 3 is sodium(1R,5S,6S)-2-[(4S)-1-methyl-2-oxo-4-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate, AMPC stands for amoxicillin and CAM stands for clarithromycin. (Test 2) Therapeutic effects for nude mouse infected with helicobacter pylori Bacteria ( helicobacter pylori 9470 strain) used for the test, which were cultured for 48 hours in a 2%-fetal-calf-serum-added brucella broth, were centrifuged. After removal of the supernatant, the residue was re-suspended in a 1/10 amount of a brucella broth. The resulting suspended solution was orally administered to each of three to five nude mice in an amount of 1.5 ml per mouse. 10 days after the infection, administration of a medicament was started. A 0.5% tragacanth suspension of a medicament was orally administered for 4 days through an oral catheter at a dose of 0.3 ml/mouse, once a day. On the day after the final administration, the stomach was extirpated, homogenized and then diluted. The viable microbe cell number (CFU/stomach) was measured and the results are shown in FIG. 1. In Fig. 1, Medicament A is a control group, Medicaments B(1) and B(2) are CAM (clarithromycin: 1mg/kg) and CAM (10 mg/kg), respectively, and Medicaments C(1) and C(2) are Compound 4, that is, pivaloyloxymethyl (1R,5S,6S)-2-[(4R)-2-oxo-4-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate (1 mg/kg) and Compound 4(10 mg/kg), respectively. The significant difference of Medicament B(2), Medicament C(1) or C(2) is p<0.01 (vs the control group). (Preparation Example 1) Capsules Compound 4 50.0 mg Lactose 128.7 Corn starch 70.0 Magnesium stearate 1.3 250 mg The above-described ingredients in powdery form were mixed, shifted through a 60-mesh sieve and used to fill a 250-mg No.3 gelatin capsule to give a capsule.

Claims: Use of a compound of formula (I), as defined below, or a pharmacologically acceptable salt or ester thereof, in the manufacture of a medicament for the prophylaxis or treatment of infectious diseases caused by helicobacter pylori: wherein: R 1 represents a group of the following formula: R 2 represents a hydrogen atom or a C 1 -C 6 alkyl group, and R 3 represents a hydrogen atom or a C 1 -C 6 alkyl group. The use according to claim 1, wherein the compound of formula (I) is one wherein R 1 is a group of formula (IIa) (in which R 2 represents a hydrogen atom or a C 1 -C 4 alkyl group), a group of formula (IIb), a group of the formula (IIc) or a group of formula (lid) (in which R 3 represents a hydrogen atom or a methyl group). The use according to claim 1, wherein the compound of formula (I) is one wherein R 1 is a group of formula (IIa) (in which R 2 represents a hydrogen atom or a methyl group). The use according to claim 1, wherein the compound of formula (I) is one wherein R 1 is a 2-oxo-3-pyrrolidinyl, 1-methyl-2-oxo-3-pyrrolidinyl, 2-oxo-4-pyrrolidinyl or 1-methyl-2-oxo-4-pyrrolidinyl group. The use according to claim 1, wherein the compound of formula (I) is one wherein R 1 is a 2-oxo-4-pyrrolidinyl or 1-methyl-2-oxo-4-pyrrolidinyl group. The use according to claim 1, wherein the compound of formula (I) is one wherein R 1 is a 2-oxo-4-pyrrolidinyl group. The use according to any one of claims 1 to 6, wherein the compound of formula (I) is one wherein the configuration in the carbapenem skeleton is a (1R,5S,6S) configuration. The use according to any one of claims 1 to 7, wherein the compound of formula (I) is one wherein the configuration of the hydroxyl group at the α-position of the 6-substituent in the carbapenem skeleton is a R configuration. The use according to any one of claims 1 to 8, wherein the salt of the compound of formula (I) is a lithium salt, sodium salt or potassium salt. The use according to any one of claims 1 to 8, wherein the salt of the compound of formula (I) is a sodium salt or potassium salt. The use according to any one of claims 1 to 8, wherein the salt of the compound of formula (I) is a sodium salt. The use according to any one of claims 1 to 11, wherein the pharmacologically acceptable ester of the compound of formula (I) is an ester which can be hydrolyzed in vivo and converted into the corresponding carboxylic acid. The use according to any one of claims 1 to 11, in which the pharmacologically acceptable ester of the compound of formula (I) is a 1-(methoxycarbonyloxy)ethyl ester, 1-(ethoxycarbonyloxy)ethyl ester, 1-(isopropoxycarbonyloxy)ethyl ester, t-butoxycarbonyloxymethyl ester, 1-(t-butoxycarbonyloxy)ethyl ester, 1-(cyclopentyloxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, acetoxymethyl ester, 1-(acetoxy)ethyl ester, isobutyryloxymethyl ester, 1-(isobutyryloxy)ethyl ester, pivaloyloxymethyl ester, 1-(pivaloyloxy)ethyl ester, cyclopentylcarbonyloxymethyl ester, 1-(cyclopentylcarbonyloxy)ethyl ester, 1-methylcyclopentylcarbonyloxymethyl ester, 1-(1-methylcyclopentylcarbonyloxy)-ethyl ester, cyclohexylcarbonyloxymethyl ester, 1-(cyclohexylcarbonyloxy)ethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester, 1-(1-methylcyclohexylcarbonyloxy)ethyl ester, phthalidyl ester, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester or 5-phenyl-2-oxo-1,3-dioxolen-4-ylmethyl ester. The use according to any one of claims 1 to 11, in which the pharmacologically acceptable ester of the compound of formula (I) is a 1-(methoxycarbonyloxy)ethyl ester, 1-(ethoxycarbonyloxy)ethyl ester, 1-(isopropoxycarbonyloxy)ethyl ester, t-butoxycarbonyloxymethyl ester, 1-(t-butoxycarbonyloxy)ethyl ester, 1-(cyclopentyloxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, acetoxymethyl ester, 1-(acetoxy)ethyl ester, isobutyryloxymethyl ester, 1-(isobutyryloxy)ethyl ester, pivaloyloxymethyl ester, 1-(pivaloyloxy)ethyl ester, cyclopentylcarbonyloxymethyl ester, 1-methylcyclopentylcarbonyloxymethyl ester, cyclohexylcarbonyloxymethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester, phthalidyl ester or 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester. The use according to any one of claims 1 to 11, in which the pharmacologically acceptable ester of the compound of formula (I) is a 1-(isopropoxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester, pivaloyloxymethyl ester, 1-methylcyclohexylcarbonyloxymethyl ester or 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester. The use according to any one of claims 1 to 11, in which the pharmacologically acceptable ester of the compound of formula (I) is a 1-(isopropoxycarbonyloxy)ethyl ester, 1-(cyclohexyloxycarbonyloxy)ethyl ester or pivaloyloxymethyl ester. The use according to any one of claims 1 to 16, in which the pharmacologically acceptable salt or ester of the compound of formula (I) is selected from the group consisting of: sodium 2-(2-oxo-4-pyrrolidinylthio)-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate, pivaloyloxymethyl 2-(2-oxo-4-pyrrolidinylthio)-6-( 1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate, 1-methylcyclohexylcarbonyloxymethyl 2-(2-oxo-4-pyrrolidinylthio)-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate, sodium 2-(1-methyl-2-oxo-4-pyrrolidinylthio)-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate, and pivaloyloxymethyl 2-(1-methyl-2-oxo-4-pyrrolidinylthio)-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate.

Inventors: KAWAMOTO ISAO, OHYA SATOSHI, UTSUI YUKIO, KAWAMOTO, ISAO, OHYA, SATOSHI, UTSUI, YUKIO, KAWAMOTO, Isao, Sankyo Company, Limited, OHYA, Satoshi, Sankyo Company, Limited, UTSUI, Yukio, Sankyo Company, Limited
Applicants: SANKYO CO, SANKYO COMPANY, LIMITED
Application year: 1997
Main classification: A61K31
IPC codes: A61P31, C07D477, A61K31, A61P1, C07D487